4SCAR-PSMA T cells
/ SZGIMI
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
June 12, 2020
PSMA-specific CAR-T Cell Therapy
(clinicaltrials.gov)
- P1/2; N=100; Recruiting; Sponsor: Shenzhen Geno-Immune Medical Institute
CAR T-Cell Therapy • Clinical • New P1/2 trial • Hematological Disorders • Oncology
1 to 1
Of
1
Go to page
1